leadf
logo-loader
viewZelira Therapeutics Ltd
(
ASX:ZLDOTCQB:ZLDAF
)

Zelda Therapeutics trade higher on medical cannabis focus

Shares have nearly tripled since the reverse takeover in late 2016.

TyraT-4_10_14_124.jpg
The company has a solid pipeline of news flow in 2017

Zelda Therapeutics (ASX:ZLD) shares have continued their strong run in 2017 trading up over 85% year to date to $0.074.

This also means that the medical cannabis company’s share price has nearly tripled since listing on the Australian Stock Exchange in November, 2016 at $0.025.

Zelda is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis.

This human data has been generated over several years by a California-based group that has a high profile within the U.S. and a growing international profile.

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.

The company expects to be commencing these trials during 2017 and have identified a relatively rapid path to commercialisation.

If successful, this could see Zelda obtaining product registrations in selected markets in 2018 with revenues flowing from there.

Quick facts: Zelira Therapeutics Ltd

Follow
ASX:ZLD

Price: 0.038 AUD

Market Cap: $45.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics enters German market through an exclusive cannabis...

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) (ASX:ZLD) (OTCQB:ZLDAF) Managing Director Dr Oludare Odumosu tells Proactive the group has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a...

5 days, 16 hours ago

2 min read